Skip to content

A clinical study on improvement of asthma control level in patients with refractory asthma by Ba-Duan-Jin lung rehabilitation exercise

A clinical study on improvement of asthma control level in patients with refractory asthma by Ba-Duan-Jin lung rehabilitation exercise

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003858
Enrollment
Unknown
Registered
2020-08-21
Start date
2021-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.People who asthma cannot be well controlled for at least 6 months after standardized treatment with two or more controlled drugs including medium and high dose ICS and long-acting beta2-receptor agonist (LABA). The criterion to achieve good Control is Asthma Control Test (ACT) score less than 20. 2.Non acute exacerbation. 3.Aged from 18~65 years.

Exclusion criteria

Exclusion criteria: 1. Wheezing caused by tuberculosis, fungus, tumor, irritant gas allergy or other respiratory diseases that may cause wheezing or dyspnea. 2. CVA. 3. Pregnant or lactating women, allergic to research drugs. 4. Complicated with cardiovascular, liver, kidney and hematopoietic system and other serious primary diseases, psychiatric patients. 5. Concurrent with severe cardiac insufficiency. 6. Combined with motor nervous system disease can not complete badanjin exercise. 7. Containing factors affecting the observation of curative effect. 8. Those who do not meet the inclusion criteria, do not use the medicine according to the regulations, cannot judge the curative effect or the incomplete data will affect the judgement of curative effect or safety.

Design outcomes

Primary

MeasureTime frame
time of acute exacerbation;6MWT;Lung function test;Remission drug use times;ACT;AQLQ;

Secondary

MeasureTime frame
SAS;SDS;

Countries

China

Contacts

Public ContactBinqing Tang
tangbinqing1979@aliyun.com+86 13636657240

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026